abstract |
The present disclosure relates generally to methods for treating a patient diagnosed with triple negative breast cancer (TNBC), involving identifying a patient likely to respond to treatment via targeted TGF-ß inhibition with an anti-TGFß agent, and treating the subject with the anti-TGFß agent. |